Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
Updates Surg. 2023 Sep;75(6):1457-1469. doi: 10.1007/s13304-023-01597-2. Epub 2023 Jul 24.
Purposes of this study are to evaluate the main changes that have occurred in the Italian MILS activity in the last decade in terms of indications, approaches and outcomes as reported in the national registry and to provide specific details on the main areas of development of MILS. Data from patients undergoing minimally invasive liver resections at centers included in the I Go MILS Registry from its start-up (November 2014) to March 2023 were analyzed for the purposes of this study. The registry is intention-to-treat and prospective. Global recruitment trends stratified by indication to surgery and type of approach were analysed. 7413 MILS procedures were performed across all centers (median number of procedures per center: 63). Years (2020-2023) displayed a significantly higher proportion of treated patients diagnosed with hepatocellular carcinoma (HCC) (38.2% vs. 28.9% and 33.9%, p < 0.001) and cholangiocarcinoma (6.7% vs. 6.5% and 4.2%, p < 0.001) compared to the preceding triennial periods. Additionally, technical complexity demonstrated an increased prominence in Years (2019-2023) with a significantly higher percentage of grade III cases compared to the earlier periods (39.3% vs. 21.7% and 25.6%, p < 0.001). Annual case trends focusing on laparoscopic and robotic techniques demonstrated a steadily increase in the use of these techniques for complex case mix of indications. Overall, attitude and attention to MILS approach has evolved, so that currently indications to hepatic mini-invasiveness have expanded and surgical technique has been refined: Areas mainly involved in increasing growth trends are hepatocellular carcinoma, possible applications of MILS in transplant setting, intrahepatic cholangiocarcinoma and robotic approach.
本研究旨在评估意大利 MILS 活动在过去十年中在适应证、方法和结果方面的主要变化,这些变化是根据国家注册中心报告的情况得出的,并提供 MILS 主要发展领域的具体细节。本研究分析了自 2014 年 11 月 I Go MILS 注册中心启动至 2023 年 3 月期间,各中心接受微创肝切除术患者的数据。该注册中心是意向治疗和前瞻性的。对按手术适应证和手术方法类型分层的全球招募趋势进行了分析。所有中心共进行了 7413 例 MILS 手术(中心平均手术例数:63 例)。2020-2023 年与前三个三年期相比,接受治疗的肝细胞癌(HCC)(38.2%比 28.9%和 33.9%,p<0.001)和胆管癌(6.7%比 6.5%和 4.2%,p<0.001)患者的比例显著增加。此外,与前几个三年期相比,2019-2023 年技术复杂性的比例明显增加,III 级病例的比例显著增加(39.3%比 21.7%和 25.6%,p<0.001)。以腹腔镜和机器人技术为重点的年度病例趋势表明,这些技术在复杂适应证病例组合中的使用稳步增加。总体而言,对 MILS 方法的态度和关注已经发生了变化,因此目前对肝微创的适应证已经扩大,手术技术也得到了改进:主要涉及增长趋势的领域是肝细胞癌、MILS 在移植环境中的可能应用、肝内胆管癌和机器人方法。